Amsterdam: The European Medicines Agency’s scientific committee wrapped up its June meeting with a batch of recommendations that stretched from a rare childhood disorder to seasonal flu, clearing six new medicines for approval and setting up a fresh round of decisions by the European Commission. The Committee for Medicinal Products for Human Use, meeting from 22 to 25 June, also backed a dozen extensions to medicines already on the market, the routine but consequential work through which the bloc’s centralised system keeps pace with new evidence.
The most closely watched of the six was Daybu, containing trofinetide, recommended for the neurobehavioural symptoms of Rett syndrome in adults and children aged five and older. Rett syndrome is a severe genetic condition that overwhelmingly affects girls and has had no approved disease-specific treatment in Europe, so a positive opinion carries weight well beyond the small number of patients it will initially reach. Families and clinicians have waited years for an option that targets the disorder rather than merely managing its complications.
The rest of the list spoke to more common concerns. Aujemflu, an inactivated influenza vaccine, was cleared to protect people aged 50 and older, a group that bears much of the seasonal burden of hospital admissions as Europe’s population ages. Onswik, a once-weekly insulin, was recommended for adults with type 2 diabetes, part of a wave of longer-acting formulations designed to ease the daily grind of injections. Hopledo, a levodopa and carbidopa combination, addresses motor fluctuations in Parkinson’s disease, while Denosumab Ascend arrives as a biosimilar to prevent bone complications in patients with advanced cancer, promising to widen access and trim costs as the reference product’s protections lapse.
Not every decision went a manufacturer’s way. The committee moved to revoke authorisation for avacopan in one setting, a reminder that the agency’s mandate runs both ways and that a green light is never permanent once real-world data accumulate. That willingness to reverse course is central to the credibility of a system built on continuous surveillance rather than one-off approvals.
A committee recommendation is not the final step. The opinions now pass to the Commission, which issues the marketing authorisations valid across all member states, usually within a couple of months. National authorities then negotiate price and reimbursement, the stage at which patients in different countries often wait very different lengths of time for the same medicine. Access to a drug approved in June may remain years away in states where health budgets are tight or bargaining is slow.
Still, the June batch underlines the scale of the EU’s centralised pathway, which spares companies from filing in 27 separate jurisdictions and gives patients a single scientific verdict. For the families watching the Rett syndrome decision most anxiously, the coming Commission sign-off cannot arrive quickly enough.
